Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGFR | P43088 | 9/20 | 0.59 |
| ▸ | TBXA2R | P21731 | 7/20 | 0.59 |
| ▸ | PTGER3 | P43115 | 6/20 | 0.59 |
| ▸ | PTGER1 | P34995 | 5/20 | 0.59 |
| ▸ | LMNA | P02545 | 3/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.59 |
| ▸ | SLCO2A1 | Q92959 | 2/20 | 0.59 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.51 |
| ▸ | PTGER2 | P43116 | 2/20 | 0.49 |
| ▸ | PTGIR | P43119 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18022096 | 0.88 | TBXA2R (0.53) | PTGFRTBXA2RPTGER3PTGER1LMNA | |
| SCHEMBL21754428 | 0.84 | ALDH1A1 (0.63) | PTGFRTBXA2RPTGER3PTGER1LMNA | |
| SCHEMBL18932223 | 0.83 | PTGFR (0.63) | PTGFRTBXA2RPTGER3PTGER1LMNA | |
| SCHEMBL12808471 | 0.82 | PTGFR (0.61) | PTGFRTBXA2RPTGER3PTGER1LMNA | |
| SCHEMBL11343326 | 0.82 | PTGFR (0.77) | PTGFRTBXA2RPTGER3PTGER1LMNA | |
| SCHEMBL11343328 | 0.82 | PTGFR (0.77) | PTGFRTBXA2RPTGER3PTGER1LMNA | |
| SCHEMBL10724938 | 0.82 | PTGFR (0.54) | PTGFRTBXA2RPTGER3PTGER1LMNA | |
| SCHEMBL8902509 | 0.81 | SLCO2A1 (0.53) | PTGFRTBXA2RPTGER3PTGER1LMNA | |
| SCHEMBL8902504 | 0.81 | SLCO2A1 (0.53) | PTGFRTBXA2RPTGER3PTGER1LMNA | |
| SCHEMBL18924923 | 0.81 | PTGFR (0.73) | PTGFRTBXA2RPTGER3PTGER1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200206309-A1 | METHODS AND COMPOSITIONS RELATED TO THE TREATMENT OF NURR1- AND PPARy-MEDIATED CONDITIONS | THE MCLEAN HOSPITAL CORPORATION | 2020-07-02 | — | — | US | disclosed |
| US-9994543-B2 | Processes and intermediates for the preparations of isomer free prostaglandins | CHIROGATE INTERNATIONAL INC. (TW) | 2018-06-12 | — | — | US | disclosed |
| US-9828356-B2 | Processes and intermediates for the preparations of isomer free prostaglandis | CHIROGATE INTERNATIONAL INC. (TW) | 2017-11-28 | — | — | US | disclosed |
| US-20160237056-A1 | NOVEL SYNTHESIS ROUTES FOR PROSTAGLANDINS AND PROSTAGLANDIN INTERMEDIATES USING METATHESIS | PATHEON API SERVICES INC. | 2016-08-18 | — | — | US | disclosed |
| US-20160237056-A1 | NOVEL SYNTHESIS ROUTES FOR PROSTAGLANDINS AND PROSTAGLANDIN INTERMEDIATES USING METATHESIS | PATHEON API SERVICES INC. | 2016-08-18 | — | — | US | disclosed |
| WO-2015048736-A1 | NOVEL SYNTHESIS ROUTES FOR PROSTAGLANDINS AND PROSTAGLANDIN INTERMEDIATES USING METATHESIS | IRIX PHARMACEUTICALS, INC. (US) | 2015-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160237056-A1 | NOVEL SYNTHESIS ROUTES FOR PROSTAGLANDINS AND PROSTAGLANDIN INTERMEDIATES USING METATHESIS | PTGES, PTGIS, PTGES2 | PTGFR 14/4885TBXA2R 35/4885PTGER3 16/4885 |
| US-20200206309-A1 | METHODS AND COMPOSITIONS RELATED TO THE TREATMENT OF NURR1- AND PPARy-MEDIATED CONDITIONS | NCOR1, PPARG, NR3C1 | PTGFR 945/4885TBXA2R 1201/4885PTGER3 2019/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.